{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:33:07Z","timestamp":1777962787608,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s00347-014-3217-7","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T13:07:31Z","timestamp":1423573651000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealit\u00e4t und Wirksamkeit bei Patienten mit neovaskul\u00e4rer altersabh\u00e4ngiger Makuladegeneration (nAMD) in Deutschland","Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany"],"prefix":"10.1007","volume":"112","author":[{"name":"AURA-Studiengruppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Eter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Radermacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Hasanbasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"3217_CR1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archopht.124.4.529","volume":"124","author":"Augood","year":"2006","unstructured":"Augood CA, Vingerling JR, De Jong PT et al (2006) Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 124:529\u2013535","journal-title":"Arch Ophthalmol"},{"key":"3217_CR2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57\u201365","journal-title":"Ophthalmology"},{"key":"3217_CR3","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258\u20131267","journal-title":"Lancet"},{"key":"3217_CR4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","volume":"33","author":"Cohen","year":"2013","unstructured":"Cohen SY, Mimoun G, Oubraham H et al (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33:474\u2013481","journal-title":"Retina"},{"key":"3217_CR5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1755-3768.2012.02493.x","volume":"91","author":"Finger","year":"2013","unstructured":"Finger RP, Wiedemann P, Blumhagen F et al (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study \u2013 a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540\u2013546","journal-title":"Acta Ophthalmol"},{"key":"3217_CR6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"Friedman","year":"2004","unstructured":"Friedman DS, O\u2019colmain BJ, Munoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564\u2013572","journal-title":"Arch Ophthalmol"},{"key":"3217_CR7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1172\/JCI71029","volume":"124","author":"Holz","year":"2014","unstructured":"Holz FG, Schmitz-Valckenberg S, Fleckenstein M (2014) Recent developments in the treatment of age-related macular degeneration. J Clin Invest 124:1430\u20131438","journal-title":"J Clin Invest"},{"key":"3217_CR8","unstructured":"Holz FG, Tadayoni R, Beatty S et al (2014) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. doi:2010.1136\/bjophthalmol-2014-305327 (Published Online First: Sep. 5, 2014)"},{"key":"3217_CR9","unstructured":"http:\/\/www.bdoc.info\/pdf\/AMD_Stellungnahme_2009.pdf. Zugegriffen: 28. Juli 2104"},{"key":"3217_CR10","unstructured":"http:\/\/www.bdoc.info\/pdf\/AMD_Stellungnahme_2010.pdf. Zugegriffen: 28. Juli 2104"},{"key":"3217_CR11","unstructured":"http:\/\/www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/000715\/WC500043546.pdf. Zugegriffen: 28. Juli 2104"},{"key":"3217_CR12","unstructured":"https:\/\/www.institut-des-bewertungsausschusses.de\/ba\/babeschluesse\/2014-06-25_ba328_2.pdf. Zugegriffen: 28. Juli 2014"},{"key":"3217_CR13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-303233","volume":"97","author":"Keenan","year":"2013","unstructured":"Keenan TD, Kelly SP, Sallam A et al (2013) Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol 97:1168\u20131172","journal-title":"Br J Ophthalmol"},{"key":"3217_CR14","unstructured":"Lucentis Lucentis Zusammenfassung; Stand: 22.01.2007"},{"key":"3217_CR15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"},{"key":"3217_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00417-012-2038-0","volume":"251","author":"Muether","year":"2013","unstructured":"Muether PS, Hoerster R, Hermann MM et al (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:453\u2013458","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3217_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000329603","volume":"47","author":"Prokofyeva","year":"2012","unstructured":"Prokofyeva E, Zrenner E (2012) Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 47:171\u2013188","journal-title":"Ophthalmic Res"},{"key":"3217_CR18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-014-3217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-014-3217-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:51:58Z","timestamp":1559051518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-014-3217-7"}},"subtitle":["Behandlungsrealit\u00e4t von Ranibizumab bei nAMD in Deutschland","Treatment reality of ranibizumab for neovascular AMD in Germany"],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1007\/s00347-014-3217-7","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}